Abbott Faces Trial Over Infant Formula
A major product-liability trial has begun in Chicago this week as Abbott Laboratories faces lawsuits alleging its infant formula caused a potentially deadly bowel disease in premature infants. The consolidated trial opened on March 4, 2026, in Cook County Circuit Court, where four families — backed by nearly 1,000 similar claims nationwide — accuse the company of failing to warn hospitals and parents that its cow’s milk-based specialized formula products can contribute to necrotizing enterocolitis (NEC) in very low-birth-weight babies.
NEC is a serious intestinal disease that occurs primarily in premature infants, sometimes leading to tissue death in the bowel, severe infections, and even death. According to court filings, the plaintiffs’ children were born prematurely between 2012 and 2019 and later developed NEC after being fed the formula at issue. While the children survived, they continue to endure long-term health complications, including surgical interventions and ongoing medical needs.
The trial is part of a wave of litigation against Abbott and also against rival maker Reckitt (via its Mead Johnson unit, the maker of Enfamil). Plaintiffs argue that both companies’ cow’s milk-based formulas increased NEC risk relative to alternatives like breast milk or human donor milk, and that manufacturers failed to provide adequate warnings. Abbott has firmly denied that its products cause NEC, saying its formulas are essential nutrition for preemies when breast milk isn’t available.
The Cook County trial consolidates four lawsuits into one proceeding, an effort by plaintiffs’ lawyers to present a bellwether case that could shape how future litigation unfolds in both state and federal courts. Jury selection began early this week, and the trial is expected to last several weeks as both sides present expert testimony on medical studies, clinical evidence, and internal corporate research.
The legal backdrop features mixed outcomes in earlier cases. Some juries in other states — particularly Missouri and Illinois — have returned substantial verdicts against Abbott and similar formula makers, while others have favored the companies or been dismissed at the summary judgment stage. A notable prior ruling saw a federal judge allow expert testimony that specialized preterm formulas might contribute to NEC, a decision that helped fuel the litigation.
Medical science around NEC remains complex and contested. Organizations such as the American Academy of Pediatrics highlight that NEC risk is strongly associated with prematurity and the absence of human milk, though there’s no firm consensus that any specific formula directly causes the disease. Research indicates that formula feeding — versus feeding with human milk — can correlate with higher NEC rates because of differences in digestive tolerance and immune protection.
In delayed cases and settlements, plaintiffs’ attorneys have argued that internal company documents could show Abbott knew about elevated NEC risk but failed to disclose it, while defense lawyers counter that no scientifically proven direct causal link exists and that infants’ medical vulnerabilities make NEC a multifactorial illness. The Cook County jury will likely be tasked with interpreting medical expert evidence, product labeling practices, and corporate conduct as part of its deliberations.
Under Illinois law, juries may be asked to decide whether Abbott’s warnings were sufficient and if the company should be held responsible for harm that families attribute to its products. Compensation could include medical expenses, long-term care costs, pain and suffering, and punitive damages, depending on what evidence jurors find credible. Plaintiffs hope this trial will influence negotiations in the broader litigation — possibly leading to larger settlements for other families with similar claims across the country.
Industry analysts are watching the trial closely because it could affect not just Abbott’s legal exposure but also other highly public product-liability cases involving nutritional products and infant safety. A large adverse verdict could trigger renewed regulatory scrutiny, more lawsuits, and shifts in how infant formulas are marketed and labeled, especially for high-risk medical populations like premature newborns.
📌 Key Legal Outcomes
-
A Chicago trial began March 4, 2026, where four families’ lawsuits against Abbott are being heard together.
-
The plaintiffs allege that Abbott’s cow’s milk-based formula caused NEC in premature infants and that warnings were inadequate.
-
Abbott denies all causal claims, asserting its products are essential and safe when used appropriately.
-
The case is among hundreds of litigation cases consolidated into broader multidistrict actions nationwide.
-
Jury selection is underway, and the trial is expected to last several weeks, with significant implications for future claims and potential settlements.
❓ Why It Matters
-
Public health impact: The trial centers on claims involving NEC — a serious, sometimes fatal disease in premature infants — raising awareness about infant nutrition safety.
-
Corporate accountability: Results could influence how formula manufacturers disclose risks and shape standards for product warnings and labeling.
-
Industry precedent: A verdict against Abbott could encourage large settlements in thousands of related lawsuits nationwide.
-
Regulatory scrutiny: Outcomes may prompt further investigation by health agencies into formula safety, research, and guidelines.
-
Consumer trust: Families, medical professionals, and the public are paying attention to how the legal system balances corporate liability against scientific uncertainty.
